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Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia Grazia Fazio, 1 * Giulia Daniele, 2 * Valeria Cazzaniga, 1 Luciana Impera, 3 Marco Severgnini, PAX5 encodes for a transcription factor essential for B-lymphoid cell commitment and is rearranged in 30% B-Cell Precursor Acute Lymphoblastic Leukemia pediatric patients (BCP-ALL) 1 . Since the first characterization of PAX5/ETV6 2 , an increasing number of PAX5 fusion genes have been described in both adult and pediatric BCP-ALL patients. As recently reviewed 3 , PAX5 fusion partners encode a variety of proteins involved in cell structure (ELN 4 
.
Herein, we report the characterization of three new PAX5 partner genes in BCP-ALL: CHFR (a novel transcript isoform), SOX5 and POM121C. Moreover, we report cases displaying PAX5/AUTS2 and PAX5/MLLT3 fusions 8, 9 .
Among 237 BCP-ALL pediatric patients enrolled in the AIEOP-BFM ALL2000 protocol for whom standard cytogenetic karyotyping was successfully performed, 35 (14.7%) presented visible abnormalities on the 9p potentially involving PAX5, and 19/35 had material available to be considered for this study. An additional adult BCP-ALL patient (n°20), carrying both a 9p abnormality in proximity of PAX5 region and a t(9;22) translocation, was also included. The patients' clinical and cytogenetic features can be found in Supplementary Table S1 .
A detailed FISH analysis 10 , using selected BAC and fosmid probes (see Supplementary Information), identified a large deletion affecting PAX5 in 14 patients (Supplementary Figure S1 and Supplementary Table S2 ) and, more importantly, a translocation involving PAX5 in 5 cases (5, 7, 10, 15, and 19) ( Figure 1A and Supplementary Table S3 ).
To determine whether these PAX5 alterations might be involved in leukemogenesis as driving genetic lesions, we further characterized PAX5-fused cases (5, 7, 10, 15, 19, and 20) , as well as their corresponding remissions using copy number variation (CNV) analysis, by Affymetrix
Cytogenetics Whole Genome Array. Data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress, accession number E-MTAB-2416). Table S5 and Figure 1B ).
In patient 15, FISH analysis identified SOX5 [SRY (sex determining region y)-Box 5] (12p12.1) as
fused to PAX5 on a dic(9;12)(p13;p12.1) dicentric chromosome ( Figure 1A ), being accompanied by losses at breakpoint regions, as confirmed by CNV analysis (Supplementary Table S5 and Figure   4 1B). RACE-PCR defined the junction as located between PAX5 exon 5 and SOX5 exon 4, confirmed by RT-PCR ( Figure 3B ). Since SOX5 and PAX5 are in opposite transcriptional orientation, we hypothesize that such fusion is the result of a complex genomic event, similarly to what described for patient 5 (see above). The occurrence of an intragenic deletion of SOX5, verified by FISH and SNP array, strongly supports this view. SOX5 encodes for a transcription factor involved in neuron development through the specific repression of target genes in the central nervous system (CNS). Intriguingly, this PAX5/SOX5 patient experienced a CNS relapse. Thus, it can be hypothesized that the chimeric protein might act as an aberrant transcription factor affecting both B-cell (through PAX5 pathway alteration) and CNS features (by SOX5 pathway alteration).
Interestingly, SOX5 has already been found fused to P2RY8 in primary splenic follicular lymphoma 11 .
In patient 19, CNV analysis detected deletions at 9p13.2 and 7q11.23, involving PAX5 and Table S5 and Figure 1B ). RNA-sequencing identified reads with PAX5 exon 6 fused to POM121C exon 4
POM121C (POM121 transmembrane nucleoporin C), respectively (Supplementary
(Supplementary Figure S3) , verified by RT-PCR ( Figure 3C ). FISH analysis confirmed the occurrence of the two copies of the fusion gene, respectively on a dicentric chromosome dic(7;9)(q11.23;p13.2) and on a second chromosome that might be the result of a further rearrangement of a second copy of the same dic(7;9) ( Figure 1A and Supplementary Figure S4) .
Notably, POM121C is a member of the same nucleoporin family as POM121, already identified as a fusion partner of PAX5 5 .
The adult B-ALL patient 20 carried a t(9;22)(q34;q11) translocation together with an additional large deletion at 9p (Supplementary Table S1 ). CNV analysis detected a 16 Mb loss between PAX5 at 9p13 and MLLT3 at 9p21.3 (Supplementary Figure S5A) . RT-PCR identified a fusion transcript joining PAX5 exon 6 to MLLT3 exon 2 (Supplementary Figure S5B) . MLLT3 is also known as AF9, which is one of the most recurrent MLL partner genes in ALL and AML. CNV analyses highlighted several genetic lesions, although most of them located in regions lacking coding genes or 5 sno/miRNAs (Supplementary Figure S5C) . This fusion gene has been already described in a B-ALL case 8 , but the patient age, as well as the association with the t(9;22) translocation, makes the genomic profile of this patient unique when compared to the other PAX5-translocated cases.
Two additional cases, patients 7 and 10, were both characterized by the presence of a t(7;9) translocation (Supplementary Table S1 ). In both patients, FISH analyses showed a deletion of the 3' portion of PAX5. The retained segment of RP11-465P6 (5'PAX5) on der(9) was found to colocalize with the splitting signals of both BAC probes specific for the 3' portion of AUTS2 (RP11-666K18, and RP11-485M20) on der(9) ( Figure 1A ) indicating the presence of PAX5/AUTS2 fusion gene in both cases, further confirmed by RACE-and RT-PCR ( Figure 3E ). CNV analysis showed the loss of the 9p with proximal breakpoint within PAX5, and loss of chromosome 7p starting from the AUTS2 gene locus (Supplementary Table S5 and Figure 1B ). PAX5/AUTS2 has been previously reported in BCP-ALL 9 .
As described in the Supplementary Information, by whole genome array analysis, we detected specific IG/TCR somatic rearrangements as a marker of the clonal origin of the leukemic cells.
Interestingly, besides the translocation events, very few additional lesions were identified, which were mainly losses (Supplementary Table S5), as described for adult PAX5-translocated cases 12 .
In details, 3 patients (7, 10 and 15) out of 5 had only one alteration in addition to the translocation, and 2 out of the 3 CNV events affected a region without known coding genes/miRNAs (UCSC database, GRCh37/hg19). Patient 5 showed 4 alterations, which were linked to two main events, such as LOH of chromosome 5 and mosaicism of chromosome 7. Particularly, FISH analysis indicated the presence of two additional clones carrying either loss or gain of chromosome 7 (30% and 20%, respectively) (data not shown).
Patient 19 carried five deletions (3 on chromosome 2). Interestingly, despite the loss of most of the 9p due to translocation, the remaining p arm and most of the q arm (on 9q32, till ZFP37 included)
were amplified (CN=3), suggesting that even the fusion gene might be duplicated, as shown by FISH ( Figure 1A and Supplementary Figure S4 ). In all the PAX5 fusions, the breakpoints in PAX5 clustered in two hot-spot regions mapping after exons 5 and 7, respectively, which retained the PAX5 DNA binding domain ( Figure 1C ). In agreement with previous findings, none of our cases expressed the reciprocal fusion transcript 5 .
The high heterogeneity of PAX5 fusion genes makes it difficult to understand the contribution of each single partner gene to leukemogenesis and the identification of shared features, except for the disruption of the physiological function of PAX5 3 . Although recent studies have indicated a functional role of PAX5 chimeric proteins [14] [15] , their exact role in leukemogenesis still remains to be fully elucidated.
Supplementary information is available at Haematologica's website.
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Supplementary Patients and Methods
Patient cohort. Among pediatric patients enrolled in the AIEOP-BFM ALL2000 protocol (for whom conventional or molecular cytogenetic analyses were available), 19 BCP-ALL presented visible abnormalities on the 9p chromosomal region, and were, therefore, considered for this study.
In addition, an adult BCP-ALL patient was analyzed, as having a 9p abnormality in addition to the t(9;22) translocation. The main patients' features are reported in Supplementary Table S1 .
FISH Analysis. It was performed on bone marrow metaphases from archival methanol:acetic acidfixed chromosome suspensions, as previously described. 1 BAC and fosmid clones were derived from the University of California Santa Cruz (UCSC) database (release of February 2009, GRCh37/hg19) and previously tested on normal human metaphases (Supplementary Tables S2-S3) . Briefly, chromosome preparations from bone marrow cells were hybridized in situ with 1µg of each Bacterial Artificial Chromosome (BAC)/fosmid probe labelled by nick translation. Hybridization was performed at 37°C in 2X SSC, 50% (vol/vol) formamide, 10% (wt/vol) dextran sulfate, 5µg COT1 DNA (Bethesda Research Laboratories, Gaithersburg, MD, USA), and 3µg sonicated salmon sperm DNA in a volume of 10 µL. Post-hybridization washings were performed at 60°C in 0.1X SSC (three times). In co-hybridization experiments, the probes were directly labeled with Fluorescein, Cy3 and Cy5 or indirectly labeled with biotin-dUTP and subsequently detected by diethylaminocoumarin (DEAC)-conjugated streptavidin. Chromosomes were identified by DAPI staining. Digital images were obtained using a Leica DMRXA epifluorescence microscope equipped with a cooled CCD camera (Princeton Instruments, Boston, MA). Cy3 (red; New England Nuclear, Boston, MA, USA), fluorescein (green; Fermentas Life Sciences, Milan, IT), Cy5 (IR; New England Nuclear, Boston, MA, USA) and DAPI (blue) fluorescence signals, which were detected using specific filters, were recorded separately as gray-scale images. Pseudocoloring and merging of images were performed with Adobe Photoshop software. Pt.5 To better clarify the complex rearrangement involving chromosomes 7 and 9 in PT19, a number of eighteen BAC clones, specific for 7p11.2, 7p14.1, 7p15.2, 7p15.3, 7p22.3, respectively, were pooled together and used as a single probe in FISH experiments.
RNA Isolation. Total RNA was extracted by the standard guanidinium thiocyanate-phenolchloroform extraction method. Rapid Amplification of cDNA Ends (RACE) Analyses. 3' RACE PCR and 5' RACE PCR were performed using commercial assays (3' RACE or 5' RACE System for Rapid Amplification of cDNA Ends, Life Technologies, Carlsbad, California, USA), according to the manufacturer's instructions. A primer specific for PAX5 exon1A was used in combination with the commercial UAP primer (3' RACE); first strand cDNA synthesis was primed using a gene-specific antisense oligonucleotide on the PAX5-partner gene sequence (5' RACE, see Supplementary Table S4 ). Gene specific primers were designed (Supplementary Table S4 ). Both 3' and 5' RACE products were cloned into a T&A cloning vector (RBC Bioscience Corporation, New Taipei City, Taiwan), and selected clones were directly sequenced, in both directions and using vector-specific M13 oligonucleotides, by the Applied Biosystems ABI-3130 Genetic Analyzer instrument (Life Technologies). Alignment was carried out using the Basic Local Alignment Search Tool database (BLAST, www.blast.ncbi.nlm.nih.gov).
RT-PCR.
One µg of total RNA was reversely transcribed with Superscript II reverse transcriptase (Life Technologies). RT-PCR was performed using a PAX5 forward primer and the reverse primer of the specific partner gene, to amplify the breakpoint region (Supplementary Table S4 ). All the RT-PCR reactions were performed in the following conditions: one step (2' at 94°C), thirty-five cycles of amplification (30 s at 94°C, 30 s at 60°C, 60 s at 72°C), using Platinum Taq DNA Polymerase (Life Technologies).
Characterization of CHFR expression in normal tissues.
To investigate the CHFR tissue-specific expression pattern, we tested cDNA from multiple tissues (bladder, brain, cervix, esophagus, heart, kidney, liver, lung, ovary, placenta, prostate, skeletal muscle, small intestine, spleen, testes, thymus, thyroid, and trachea) (First Choice Total RNA Survey Panel, Catalog No. AM6000, Ambion, Milan, Italy), together with cDNA from fetal brain RNA, peripheral blood, and bone marrow (Clontech, Saint-Germain-en-Laye, France). cDNA was obtained by reverse transcription using the QuantiTect Reverse Transcription Kit (Qiagen) and amplified by the Applied Biosystems Real-Time PCR System 7300 in the presence of 1X Platinum ® SYBR Green qPCR SuperMix-UDG with ROX (Life Technologies), and 300nM of each sense and antisense primer. All measurements were performed at least in triplicate. The PCR conditions were as it follows: 2 min at 50°C, 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C for all the primer pairs used. Melting curves were acquired and analyzed to control the specificity. Two primer pairs, corresponding to the CHFR wild-type and novel transcript isoform, were designed to amplify products of 65 and 133 bp, respectively. Primer sequences are reported in the Supplementary Table S4 . The gene expression level was calculated using the relative quantification approach based on the ∆∆Ct method.
3 In all the experiments, GAPDH gene was used as reference, and normal bone marrow as calibrator.
RNA-Seq Analysis
Total RNA was checked for integrity and purity by capillary electrophoresis (Agilent Bioanalyser 2100, Agilent Technologies, Santa Clara, CA, USA), requiring a RNA Integrity Number of 8 or more. 2µg RNA was used to prepare a double-stranded cDNA library for high-throughput sequencing by Truseq RNA kit (Illumina, San Diego, CA, USA). 6pM of the library was loaded in one lane of an Illumina flowcell, subjected to cluster bridge amplification in a cBot station and paired-end sequenced on a GAIIx instrument with a 2×76 protocol (Illumina pipeline version 1.6). After sequencing run completion, clusters were converted into reads by using Illumina's proprietary software OLB (Offline BaseCaller, v.1.9.0). Raw reads were mapped against the University of California Santa Clara (UCSC) human genome sequence, release 19 (hg19) by using BWA (v. 0.5.9, allowing up to 3 mismatches in the alignment and a trimming of bases having a phred quality below 15). 4 Not perfectly mapped or trimmed read pairs (i.e.: those having at least one unmapped mate, more than 7 trimmed bases, or more than 1000 nt between the two mates) were re-aligned against hg19 and RefSeq gene models (http://www.ncbi.nlm.nih.gov/refseq/) by TopHat (v. 1.3.1, allowing up to 3 mismatches). 5 Reads having at least one unmapped pair, or characterized by a distance between the two mates above 1000 nucleotides were used as an input to FusionMap software (v. 6.2.1.41, using Human B37 and RefSeq as reference genome and transcriptome model, respectively) 6 to search for genomic rearrangements. Candidate events derived from FusionMap were further filtered as follows: a) We kept only those events having 3 or more non-clonal supporting reads b) We excluded events eventually localized in repeated regions of the genome and specifically:
-all the records in FusionMap output sharing one of the breakpoints (even though they had a different mate); -candidates having the whole junction region (i.e. 60 nt across the junction) completely matched anywhere in the reference genome (in order to compensate for transcripts whose structure was not considered in FusionMap). This was assessed by means of a Blat 7 alignment against the hg19 reference; -candidates having either of the two halves (i.e. length=30 nt) of the junction matching in multiple locations of the genome according to their Blat alignment. c) We required a coverage of at least 10 reads in the regions flanking the rearrangement, in order to exclude those regions not sufficiently covered by sequencing reads to have a reliable characterization. Sequencing coverage was calculated by using the utility samtools (v. 0.1.17, command mpileup); 8 d) We filtered out the events having an incidence of the reads supporting the fusion event below 10% of the total reads on either side.
Copy Number Variation analysis. Five diagnostic samples (patients 5, 7, 10, 15 and 19), as well as their corresponding remission specimens, were genotyped by the Affymetrix Cytogenetics Whole Genome 2.7M Array (Affymetrix, Santa Clara, CA), while patient 22 has been analyzed by Genome-Wide Human SNP Array 6.0 (Affymetrix). The Affymetrix® Cytogenetics Whole Genome 2.7M and 6.0 Arrays provide dense coverage across the entire genome due to high number of markers, including 400,000 SNPs and 2.3 millions of non-polymorphic copy-number markers. Therefore, it enables to detect small aberrations (gains/losses) and copy number neutral loss of heterozygosity (LOH) regions. Briefly, 100ng of genomic DNA were amplified by an overnight whole-genome amplification reaction and purified by magnetic beads according to the manufacturer's instructions. The samples were then fragmented to generate small (<300 bp) products which were subsequently biotin-labeled, denatured and loaded into the arrays. After hybridization, the chips were washed, stained (streptavidin-PE), and scanned using the Gene Chip® Scanner 3000. Affymetrix GeneChip Command Console™ (AGCC) v3.1 generated .CEL files, which were analyzed by Chromosome Analysis Suite software (Affymetrix). A minimum number of 20 markers and a minimal length of 100 Kb and 50 Kb, respectively were considered for defining amplified and deleted regions. No extra signal for the probe specific for CHFR was observed on der(9). Consequently, being aware that CHFR shows an opposite transcriptional orientation to PAX5 and that a simple t(9;12) translocation could not generate an inframe fusion, we hypothesize that a cryptic rearrangement involving CHFR (i.e. not detectable at the level of FISH resolution) should have necessarily occurred prior or at the time of the translocation. Figure S3 . POM121C/PAX5 fusion gene by RNA-Seq analysis. Mapping of reads on hg19 reference sequence (from UCSC genome browser) is shown in the upper part of the plot. Sequencing reads supporting the fusion are shown as mapping across the ad-hoc built reference of the fusion transcript. The blue track displays the depth of coverage across the junction. Figure S4. FISH results obtained in patient 19 . A-FISH pseudocolor merged image, and raw images corresponding to each probe labeled with a different fluorochrome. RP11-1054F23 (mapping at the 3' end of POM121C) displayed splitting signals on both dic(7;9) and der(9)t(?;7;9) chromosomes, apart from a signal on the normal chromosome 7. This result indicates that there are two copies of the PAX5/POM121C fusion gene, since RP11-1054F23 co-localizes with the PAX5 probes on both dic(7;9) and der(9) (see also Figure 1A ). Conversely, RP11-93G19 was used in a pool of probes together with all the BACs listed in the Supplementary Table S3 (and indicated by a double asterisk) and mapping on the short arm of chromosome 7. This pool of probes [behaving as a Partial Chromosome Painting (PCP) of 7p] displayed signal on the normal chromosome 7, on the dic(7;9) and on a marker chromosome [that we indicated as der(?)t(?;7)], possibly resulting from a further rearrangement (translocation) of a second copy of the dic(7;9) with a chromosome of unknown origin (indicated as chr?). B-The results of each informative hybridization are illustrated by coloured circles corresponding to every single used probe. 
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deleted-PAX5/MLLT3
M=male; F=female; cALL=common Acute Lymphoblastic Leukemia; WBC count= number of white blood cells/µl; na=not available. 
